As the classification accuracy of the spectra acquired from each individual is relatively high (>52%, for all individuals with the exception of individual 99), the RS-GBR-NMF-sparseLDA method could potentially eliminate the need for post-treatment IHC if Ki67 is a useful prognosticator for treatment success in HDR-BT treatment for prostate cancer. Here, MKI67 is linked to prostate carcinoma.